Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,799 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07551804RecruitingPhase 2
Growth hormone replacement therapy safety and effectiveness study
This study tests a new injectable growth hormone treatment for adults whose bodies don't produce enough growth hormone naturally. Researchers will measure how safe it is, how your body processes it, and whether it helps you feel better and function more normally.
BeijingAges 18–80 - NCT06565689RecruitingPhase 1
YK012 for B-cell non-Hodgkin lymphoma after prior treatments
This study tests a new daily pill called YK012 for people with certain types of B-cell non-Hodgkin lymphoma that have not responded to at least two prior treatments. The goal is to see if it is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18–65 - NCT03619850RecruitingPhase 3
Ferumoxytol vs iron sucrose for child kidney anemia
This study compares two IV iron treatments—ferumoxytol and iron sucrose—to treat iron deficiency anemia in children with chronic kidney disease. It aims to see which option works better and is safe, and also to learn how each medicine behaves in the body.
Hollywood, FloridaAges 2–17 - NCT04471987RecruitingPhase 1
IL-12 drug for metastatic cancer after checkpoint therapy
This Phase 1 trial studies the safety of an investigational drug called IL-12-L19L19 and looks for early signs it may help control advanced (metastatic) solid tumors. It is designed for people whose cancer has continued to grow even after treatment with immune “checkpoint” therapies.
Hamburg, Free and Hanseatic City of HamburgAges 18–80 - NCT05690581RecruitingPhase 1
CM369 for advanced cancers with special immune marker in tumors
This Phase 1 study tests how safe and tolerable CM369 is in people with advanced solid tumors or blood cancers. It also looks at how the drug behaves in the body and whether it can help shrink or control cancer, especially when a tumor marker called CCR8 is present.
Guangzhou, GuangdongAges 18–75 - NCT05778188RecruitingPhase 2
RLS-0071 for newborns with moderate or severe HIE
This trial studies whether RLS-0071 is safe and can help some newborns with moderate or severe hypoxic-ischemic encephalopathy (HIE), a brain injury caused by low oxygen around birth. Babies in the study also receive standard whole-body cooling (therapeutic hypothermia), and the researchers will watch for side effects and early signs of benefit.
Little Rock, ArkansasAges Up to 10 hours - NCT05806099RecruitingPhase 1/Phase 2
Study of MBS303 for CD20-positive B-cell lymphoma that returned
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
BeijingAges 18 years+ - NCT06186414RecruitingPhase 1
SIM0237 with or without BCG for bladder cancer
This trial tests a new drug, SIM0237, alone or with BCG, for people with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that did not respond to BCG treatment. The goal is to see if it is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06235437RecruitingPhase 1
Testing a new drug (ASD141) for advanced solid tumors
This early-phase trial tests a new drug called ASD141 for people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if it is safe and how well it works against the cancer.
TainanAges 18 years+ - NCT06429176RecruitingPhase 2
SPL84 for cystic fibrosis with 3849+10kb mutation
This trial tests a new drug called SPL84 for people with cystic fibrosis who have a specific gene mutation (3849+10kb C->T). It aims to see if the drug is safe and can improve lung function. The study has two paths: one for people not taking certain CF drugs, and one for those who are already on Trikafta or Alyftrek.
Los Angeles, CaliforniaAges 18 years+ - NCT06515470RecruitingPhase 1
Testing BTX-9341 for advanced breast cancer
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Rochester, MinnesotaAges 18 years+ - NCT06690476RecruitingEarly Phase 1
Study of IPM514 for esophageal cancer
This trial tests a new drug called IPM514 for people with a type of esophageal cancer (squamous cell). It aims to find out if the drug is safe and effective. The trial has different groups for those who have had prior treatment and those who will have surgery after treatment.
BeijingAges 18 years+ - NCT05987449RecruitingPhase 1/Phase 2
Study of NXT007 for severe or moderate hemophilia A
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
Sacramento, CaliforniaAges 2–59 - NCT06826196RecruitingPhase 1/Phase 2
Testing a new shot for patchy hair loss (alopecia areata)
This study tests a new medicine called ALD-102, given as a small shot in the scalp, to see if it helps hair grow back in people with alopecia areata. It is an early-stage trial looking at safety, how the body handles the drug, and whether it works.
Thousand Oaks, CaliforniaAges 18–55 - NCT06869863RecruitingPhase 1/Phase 2
Study of MediReg® for severe male infertility
This study tests an experimental medicine called MediReg® for men with severe infertility who have not been able to conceive. It aims to see if the drug is safe and can improve sperm quality, possibly offering a new option for men who have not had success with other treatments.
Moscow, MoscowAges 21–60 - NCT06938867RecruitingPhase 1/Phase 2
Study of SNIPR001 for resistant gut bacteria before stem cell transplant
This study tests an experimental oral medicine called SNIPR001. It is designed to reduce resistant E. coli bacteria in the gut before your stem cell transplant, possibly lowering the risk of infection.
Duarte, CaliforniaAges 18 years+ - NCT06956690RecruitingPhase 1/Phase 2
Testing HMBD-501 for HER3-positive advanced solid tumors
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06959706RecruitingPhase 1
Study of TGW101 for advanced solid tumors
This trial tests a new drug called TGW101 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and may help shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT07048197RecruitingPhase 1/Phase 2
Study of cell therapy for rheumatoid arthritis and Sjogren's disease
This trial tests a new cell therapy (Rapcabtagene Autoleucel) to see if it's safe and might help people with rheumatoid arthritis or Sjogren's disease who haven't responded to standard treatments.
BordeauxAges 18–75 - NCT07102342RecruitingPhase 1/Phase 2
Cell therapy for Parkinson's disease
This trial tests a new cell treatment for Parkinson's disease. It involves injecting special cells into the brain to see if they can safely replace damaged cells and improve symptoms. It might help people who have had Parkinson's for several years and still respond well to medication.
New York, New YorkAges 30–75 - NCT07148128RecruitingPhase 1/Phase 2
Testing the safety of WEF-001 for KRAS-mutant cancers
This trial studies a new drug called WEF-001 for people with advanced cancers that have a KRAS mutation. It aims to see if the drug is safe and shrinks tumors when used alone.
Dallas, TexasAges 18 years+ - NCT07249879RecruitingPhase 1
CAR-T cell therapy for DLL3-positive small cell lung cancer
This trial tests a new CAR-T cell therapy (GC511B) for people with a specific type of small cell lung cancer that has DLL3 protein. The treatment uses your own immune cells to target and attack the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07334119RecruitingPhase 1
Testing MT-304 for advanced HER2-positive tumors
This trial tests a new drug, MT-304, for people with advanced cancers that have high levels of a protein called HER2. It aims to see if the drug is safe and helps shrink tumors.
Darlinghurst, New South WalesAges 18 years+ - NCT07404033RecruitingPhase 1
Testing a lotion for mild to moderate dandruff rash
This trial tests a new lotion for people with mild to moderate seborrheic dermatitis (a common skin condition causing red, scaly patches on the scalp, face, or chest). The study checks safety and how well the lotion works.
Suzhou, JiangsuAges 18–65
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,799 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.